ArticleThe International journal on drug policy2025
Differential risk for Hepatitis C and HIV among people who inject drugs in Kenya: a latent class analysis signaling needs for innovation in service delivery.
Article in The International journal on drug policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSubgroups of people who inject drugs (PWID) may experience differential exposure to HIV and hepatitis C (HCV). This study analyzes behavioral risk profiles associated with HIV and HCV infection among PWID, with the aim of identifying subgroups at highest risk and guiding future interventions.
methodsWe recruited PWID in Kenya using respondent driven sampling. Participants completed behavioral surveys and point-of-care HCV, HIV, and hepatitis B (HBV) testing. We used latent class (LC) analysis to divide the sample into mutually exclusive classes based on nine risk- and service access-related measures.
resultsAmong the 3152 participants enrolled, one-fifth (N = 610, 19.4 %) were HCV antibody-positive, one-tenth were HIV-positive (N = 306, 9.7 %), and 1.3 % (N = 40) were HBV-positive. We obtained three LCs: LC1 - long-term, high-frequency PWID with large networks, high access to NSP services, and moderate access to OAT (N = 1522, 48.3 %), LC2 - newer, high-frequency PWID with large networks, moderate access to NSP services, and moderate access to OAT (N = 878, 27.8 %), and LC3 - long-term, low-frequency PWID with small networks, high access to NSP, and moderate access to OAT (N = 752, 23.9 %). HIV and HCV prevalence and risk behaviors differed between the classes, and classes differed in demographic characteristics as well.
conclusionSubgroups of PWID in Kenya have different risk for HIV and HCV, influenced by duration of injection, network size, service access, and other behavioral risk factors. Targeted interventions to meet each subgroup's needs are essential to prevent ongoing HCV and HIV epidemics among PWID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.